High Prevalence of Hepatitis B Virus Drug Resistance Mutations to Lamivudine Among People with HIV/HBV Coinfection in Rural and Peri-Urban Communities in Botswana
(1) Background: We aimed to determine the prevalence of hepatitis B virus (HBV) resistance-associated mutations (RAMs) in people with HBV and human immunodeficiency virus (HBV/HIV) in Botswana. (2) Methods: We sequenced HBV from participants with HBV/HIV from the Botswana Combination Prevention Project study (2013-2018) using the Oxford Nanopore GridION platform. Consensus sequences were analyzed for genotypic and mutational profiles. (3) Results: Overall, 98 HBV sequences had evaluable reverse transcriptase region coverage. The median participant age was 43 years (IQR: 37, 49) and 66/98 (67.4%) were female. Most participants, 85/97 (87.6%) had suppressed HIV viral load (VL). HBV RAMs were identified in 61/98 (62.2%) participants. Most RAMs were in positions 204 (60.3%), 180 (50.5%) and 173 (33.3%), mostly associated with lamivudine resistance. The triple mutations, rtM204V/L180M/V173L and was the most predominant (17/61 [27.9%]). Most participants (96.7%) with RAMs were on antiretroviral therapy for a median duration of 7.5 years (IQR: 4.8, 10.5). Approximately 27.9% (17/61) of participants with RAMs had undetectable HBV VL, 50.8% (31/61) had VL <2000IU/mL and 13/61 (21.3%) had VL ≥2000 IU/mL. (4) Conclusions: The high prevalence of lamivudine RAMs discourages the use of ART regimens with 3TC as the only HBV-active drug in people with HIV/HBV..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Preprints.org - (2024) vom: 18. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Phinius, Bonolo B. [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.20944/preprints202403.0750.v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
preprintsorg042919193 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | preprintsorg042919193 | ||
| 003 | DE-627 | ||
| 005 | 20240419120456.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.20944/preprints202403.0750.v1 |2 doi | |
| 024 | 7 | |a 10.20944/preprints202403.0750.v1 |2 doi | |
| 035 | |a (DE-627)preprintsorg042919193 | ||
| 035 | |a (preprintsorg)10.20944/preprints202403.0750 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Phinius, Bonolo B. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a High Prevalence of Hepatitis B Virus Drug Resistance Mutations to Lamivudine Among People with HIV/HBV Coinfection in Rural and Peri-Urban Communities in Botswana |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a (1) Background: We aimed to determine the prevalence of hepatitis B virus (HBV) resistance-associated mutations (RAMs) in people with HBV and human immunodeficiency virus (HBV/HIV) in Botswana. (2) Methods: We sequenced HBV from participants with HBV/HIV from the Botswana Combination Prevention Project study (2013-2018) using the Oxford Nanopore GridION platform. Consensus sequences were analyzed for genotypic and mutational profiles. (3) Results: Overall, 98 HBV sequences had evaluable reverse transcriptase region coverage. The median participant age was 43 years (IQR: 37, 49) and 66/98 (67.4%) were female. Most participants, 85/97 (87.6%) had suppressed HIV viral load (VL). HBV RAMs were identified in 61/98 (62.2%) participants. Most RAMs were in positions 204 (60.3%), 180 (50.5%) and 173 (33.3%), mostly associated with lamivudine resistance. The triple mutations, rtM204V/L180M/V173L and was the most predominant (17/61 [27.9%]). Most participants (96.7%) with RAMs were on antiretroviral therapy for a median duration of 7.5 years (IQR: 4.8, 10.5). Approximately 27.9% (17/61) of participants with RAMs had undetectable HBV VL, 50.8% (31/61) had VL <2000IU/mL and 13/61 (21.3%) had VL ≥2000 IU/mL. (4) Conclusions: The high prevalence of lamivudine RAMs discourages the use of ART regimens with 3TC as the only HBV-active drug in people with HIV/HBV. | ||
| 700 | 1 | |a Anderson, Motswedi |e verfasserin |4 aut | |
| 700 | 1 | |a Gobe, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Mokomane, Margaret |e verfasserin |4 aut | |
| 700 | 1 | |a Choga, Wonderful T. |e verfasserin |0 (orcid)0000-0001-7606-0569 |4 aut | |
| 700 | 1 | |a Mokomane, Margaret |e verfasserin |4 aut | |
| 700 | 1 | |a Choga, Wonderful T. |e verfasserin |4 aut | |
| 700 | 1 | |a Mpebe, Gorata |e verfasserin |4 aut | |
| 700 | 1 | |a Makhema, Joseph |e verfasserin |4 aut | |
| 700 | 1 | |a Shapiro, Roger |e verfasserin |4 aut | |
| 700 | 1 | |a Lockman, Shahin |e verfasserin |4 aut | |
| 700 | 1 | |a Musonda, Rosemary |e verfasserin |4 aut | |
| 700 | 1 | |a Moyo, Sikhulile |e verfasserin |4 aut | |
| 700 | 1 | |a Gaseitsiwe, Simani |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Preprints.org |g (2024) vom: 18. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:18 |g month:04 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/v16040592 |x 0 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.20944/preprints202403.0750.v1 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a preprintsorg | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 18 |c 04 | ||